MUTHU RAJA, Karthick Raja, Martin PLÁŠIL, Lucie ŘÍHOVÁ, Jana PELCOVÁ, Zdeněk ADAM and Roman HÁJEK. Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment (Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone treatment). Cytometry Part B ( Clinical cytometry). HOBOKEN: WILEY-BLACKWELL, 2014, vol. 86, No 4, p. 220-228. ISSN 1552-4949. doi:10.1002/cyto.b.21109.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment
Authors MUTHU RAJA, Karthick Raja (356 India, belonging to the institution), Martin PLÁŠIL (203 Czech Republic), Lucie ŘÍHOVÁ (203 Czech Republic, belonging to the institution), Jana PELCOVÁ (203 Czech Republic), Zdeněk ADAM (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor, belonging to the institution).
Edition Cytometry Part B ( Clinical cytometry), HOBOKEN, WILEY-BLACKWELL, 2014, 1552-4949.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.398
RIV identification code RIV/00216224:14110/14:00073417
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/cyto.b.21109
UT WoS 000340544300001
Keywords in English CD8 T regulatory cells; multiple myeloma; immune suppression; lenalidomide; dexamethasone; flow cytometry and CFSE
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 23. 10. 2014 15:48.
Abstract
Background: Multiple myeloma (MM) is a malignancy of plasma cells frequently associated with immune abnormalities. Several studies have confirmed that in MM immune deregulation can be mediated by increased numbers of CD4 T regulatory (Treg) cells, and these cells were also associated with poor outcome. In this study, we aimed to study CD8 Treg cells before and after lenalidomide plus dexamethasone (len-dex) treatment in MM patients. Methods: Using flow cytometry, we enumerated and assessed suppressive function of CD8 Treg cells in 16 MM patients before and after len-dex treatment. Results: Numbers of CD8 Treg cells (CD8+CD25hi+FoxP3+) (P < 0.01) were significantly increased in MM patients (before treatment) compared to healthy donors. However, no significant changes were observed in CD4 and CD8 T cells. A significant increase in CD8 Treg cells was observed after len-dex treatment compared to pre-treatment but no significant difference was observed in CD4 and CD8 T cells. Proliferation assay data showed that CD8 Treg cells inhibited proliferation of CD4 T cells and IFN-gamma secretion in a concentration dependent manner. Suppressive activity of CD8 Treg cells did not differ significantly between healthy donors, untreated and len-dex treated MM patients. A significant abnormal level of IL-10 was observed from proliferation assays of untreated and len-dex treated MM patients compared to healthy donors (P <= 0.03). Conclusions: Using flow cytometry, we have shown that suppressive CD8 Treg cells are increased in MM patients and len-dex treatment is unable to control these suppressive CD8 Treg cells. (C) 2013 International Clinical Cytometry Society
Links
GAP304/10/1395, research and development projectName: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií
Investor: Czech Science Foundation
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
PrintDisplayed: 1. 7. 2022 05:22